echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The official topping of the Lvgu sugar drug production base is expected to benefit Alzheimer's patients worldwide

    The official topping of the Lvgu sugar drug production base is expected to benefit Alzheimer's patients worldwide

    • Last Update: 2021-11-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Shanghai, October 11, 2021/PRNewswire/ - On September 29, the main structure of the Green Valley Sugar Drug Production Base in Shanghai International Medical Park was officially completed and the main structure was fully capped.
    This is since the start of the foundation stone laying on July 17, 2020 An important development

    .
    Following the Shanghai Qingpu base and the Liaoning Benxi base, this will be the third GMP standard production base of Green Valley Pharmaceuticals, and it will also be the world's first sugar drug production base that meets China and the United States GMP standards.
    It is committed to ensuring production quality and In line with international standards, as China's first production base for exporting sugar drugs to the world, it carries the important mission of the internationalization of China's original drugs, which is expected to benefit patients with Alzheimer's disease (AD) worldwide

    .

    The total investment of the project is 1.
    227 billion yuan, and the area will reach 55,000 square meters.
    It is expected to be completed and put into operation before the end of 2024.
    The production capacity of Gu's subsequent series of sugar drugs, the annual output of mannite sodium capsules will reach 6 billion capsules, meeting the medication needs of more than 2.
    4 million patients with Alzheimer's disease

    .

    Alzheimer's disease has become one of the diseases that seriously endanger the health and quality of life of the global elderly
    .
    According to the 2019 Global Health Estimates Report released by the World Health Organization in 2020, in the past 20 years, among the top ten causes of death in the world, Alzheimer's disease and other forms of dementia alone have been among the top ten causes of death in the world

    .
    According to data from the seventh national census, China’s current population over 60 accounts for 18.
    7% of the total population.
    With the gradual aggravation of China’s aging problem, the incidence of Alzheimer’s disease will gradually increase

    .
    At present, there are about 10 million Alzheimer's disease patients in China, and it is estimated that by 2050, it will exceed 40 million

    .

    Sugar science and sugar medicine have become an important part of life science research and new drug research and development in the 21st century.
    Scientific research has found that sugar is not only an energy substance in traditional cognition, but also participates in some key steps in life genetics and biosynthesis.
    [1]

    .
    Studies have shown that sugar drugs have a variety of biological activities such as anticoagulation, hypolipidemic, antibacterial, antiviral, antitumor, anti-aging and immune enhancement [2], which means that the development of sugar drugs will be used in clinical medicine and biological sciences in the future.
    Play a more important role in the field

    .

    China's original innovative drug, Ganlut Sodium Capsules, is one of the representatives of the successful development of sugar drugs, which has been approved for listing on November 2, 2019
    .
    Mannat Sodium Capsules is a low-molecular-weight acid oligosaccharide compound prepared with marine brown algae extract as raw material.
    It is not only the world’s first anti-Alzheimer’s disease carbohydrate drug, it also fills the world’s 17-year-old disease field.
    There is a gap in the listing of new drugs

    .
    As a disease-modifying drug that acts on the mechanism of the brain-gut axis, Ganlutner Capsule breaks the long-term dilemma of no new drugs available in the AD field in China, and provides new treatment options for AD patients in China

    .

    As an innovative pharmaceutical company driven by R&D, Green Valley Pharmaceuticals always adheres to the holistic view and the "brain-gut axis" theory as the core, and uses sugar drugs as the means to explore treatments for humans to overcome chronic and complex diseases, and to develop the most anticipated drugs for patients.
    Improve human cognitive health

    .
    Green Valley Pharmaceutical has accumulated more than 20 years of theory, experience and technology in the field of sugar drug innovation.
    Green Valley Research Institute has extracted, separated and chemically modified more than 7,500 polysaccharides and oligosaccharides from thousands of plants, microorganisms and marine organisms.
    Sugar samples have formed an internationally leading sugar compound library with independent intellectual property rights.
    Based on this, a unique sugar drug research and development pipeline has been established, including dozens of preclinical lead compounds, covering tumors, neuropsychiatric diseases, Many major diseases such as autoimmune diseases

    .

    At present, the international multi-center phase III clinical trial of Ganlut Sodium Capsules has been fully carried out.
    This is a 52-week multi-center randomized, double-blind, double-arm, parallel group placebo-controlled, monotherapy clinical trial.
    It will be launched in North America and Europe.
    Approximately 200 clinical centers were established in 14 countries and regions including China and China, involving 2,046 patients with mild to moderate Alzheimer's disease

    .
    After the double-blind period, a 26-week open trial will be carried out

    .
    Its 52-week double-blind study plan will be completed in 2025, and the new drug registration and marketing work in Europe and the United States will be carried out afterwards, which is expected to benefit AD patients worldwide

    .

    references:

    [1] Yin Jian, Ye Xinshan.
    Glycochemistry: An important driving force for the research and development of carbohydrate drugs[J].
    Advances in Pharmacy, 2020, 44(7):481-483

    [2] Wu Ligen, Mao Wenjun.
    Research progress on the biological activity of derivatized polysaccharides[J].
    Marine Science, 2002, 26(5):23-25

    Source: Green Valley Pharmaceutical

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.